$25.75
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 7,802 full-time employees. The company went IPO on 2008-05-08. The company is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company also operates a Enovis Growth eXcellence business system (EGX).
Country

US

CEO

Mr. Damien Mcdonald

IPO date

2008

Employees

7,802

ISIN

US1940145022

Key stats

Open

$25.60

Volume

1.97M

Market cap

$1.45B

Prev. close

$25.22

Impl / hst vl

-

Open interest

$0.00

$24.83

Day’s Range

$25.85

$19.14

52W Range

$29.89

Valuation

50
Valuation score
Fairly Valued
P/E
-
P/S
0.60
P/B
0.92
Current ratio
2.04
Debt / Equity
0.88
ROE
-60.13%
Gross margin
62.04%
Income growth
-98.32%
FCF growth
-189.36

Analysts estimates

Consensus rating
Buy

The average rating from top 9 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$43.15
The top 12 analysts forecasts that 12-month price may increase by 67.56%, with a low of $33.33 and a high of $57.75
$33.33
Low
$43.15
Avg
$57.75
High
Current price

Earnings

Q2 ‘26 revenue
$589.15M
Q2 ‘26 net income
-$8.76M
Revenue
Net income
Previous EPS
$0.89
Estimate EPS
$0.87
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply